Cerbios-Pharma gains new director of commercial business development
Will help firm to grow and strengthen HPAPI services
Prior to joining Cerbios, Console was business and financial director at Micro-Macinazione.
Cerbios-Pharma is a Swiss firm based in Lugano specialising in the development and manufacturing of chemical and biological APIs.
APIs made by Cerbios cover small molecules (Chemical Division), large molecules and probiotics (Biological Division).
The Chemical Division specialises not only in reduced folates, but also in the manufacturing of High Potency Active Ingredients (HPAIs) with long-term experience in Vitamin D derivatives requiring sophisticated production units with high containment levels.
The Biological Division specializes in the research, development and production of Probiotics as active pharmaceutical ingredients, pharmaceutical finished products and feed additives.
You may also like
Manufacturing
Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market
Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
Ingredients
Pangea Pharmaceuticals launches FDA-approved amlodipine oral solution Sdamlo
Pangea’s Sdamlo, the first FDA-approved amlodipine powder for oral solution, leverages a patent-pending lyophilisation process to enable precise unit-dose delivery and improved administration for paediatric, geriatric and dysphagic patients
Ingredients
Oncodesign Services extends GIP ARRONAX collaboration to secure astatine-211 supply
The company has extended its collaboration with the French radionuclide specialist to secure access to astatine-211, an alpha-emitting radioisotope of growing interest in targeted radiotherapy but constrained by its seven-hour half-life and limited production capacity